Abbott Laboratories (ABT)
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know
The latest trading day saw Abbott (ABT) settling at $133.17, representing a +0.79% change from its previous close.
Expanding Diabetes Business Supports ABT Stock, FX Issues Stay
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
Most companies don't survive for decades, much less pay regular dividends for that long. However, some rare corporations can pull it off.
ABT Stock Jumps 12% Since Q4 Earnings: Time to Invest in Abbott?
Abbott projects organic sales growth between 7.5% and 8.5% for 2025.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
3 No-Brainer Healthcare Stocks to Buy With $200 Right Now
Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative biotech that may launch game-changing products down the road.
Why We Chose Abbott Labs Stock Amid Tariff And DeepSeek Volatility
The last few weekends have been roiled by headlines. Here's why we took a different direction on this medical stock this week.
Here are the best performing dividend aristocrats stocks in 2025
Dividend aristocrat stocks have largely done well in the past few years. The closely-followed ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has jumped by over 133% from its lowest level in 2020.
2 Unstoppable Dividend Stocks That Will Pay You for Life
In the past few years, some high-profile dividend stocks have reduced their payouts, much to the chagrin of investors. As most income seekers want to avoid this fate, they might consider turning to arguably the most elite group of dividend payers on the market: Dividend Kings.
My Best Dividend Aristocrats For February 2025
The ProShares S&P 500 Dividend Aristocrat ETF posted its 3rd worst monthly return in December, falling by 7.69%. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 42 months of tracking these strategies, two strategies are generating a CAGR superior to NOBL.
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
